Sensitivity analysis comparing differences in school enrolment between HPTN 068 trial participants in the control arm only and non-trial participants
| Enrolment | n | Per cent enrolled | RD (95% CI) | aRD* (95% CI) | |
| 2011: full cohort | |||||
| All ages | |||||
| Trial participant (control) | 862 | 872 | 98.9 (98.2, 99.6) | 6.0 (4.7 to 7.3) | 3.2 (−1.4 to 7.7) |
| Non-trial participant | 1871 | 2015 | 92.9 (91.7, 94.0) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 543 | 544 | 99.8 (99.5, 1.00) | 0.6 (0.0 to 1.3) | 0.4 (−7.3 to 8.0) |
| Non-trial participant | 1115 | 1124 | 99.2 (98.6, 99.7 | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 280 | 285 | 98.3 (96.7, 99.8) | 6.5 (3.8 to 9.1) | 5.7 (−0.9 to 12.3) |
| Non-trial participant | 593 | 646 | 91.8 (89.7, 93.9) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 39 | 43 | 90.7 (82.0, 99.4) | 24.2 (13.7 to 34.7) | 17.7 (2.6 to 32.8) |
| Non-trial participant | 163 | 245 | 66.5 (60.6, 72.4) | 1 | 1 |
| 2015: full cohort | |||||
| All ages | |||||
| Trial participant (control) | 653 | 813 | 80.3 (77.6, 83.1) | 11.8 (8.3 to 15.3) | 6.9 (3.6 to 10.3) |
| Non-trial participant | 1231 | 1797 | 68.5 (66.4, 70.7) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 448 | 504 | 88.9 (86.2, 91.6) | 4.8 (1.2 to 8.3) | 2.4 (−1.3 to 6.1) |
| Non-trial participant | 833 | 990 | 84.1 (81.9, 86.5) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 186 | 269 | 69.1 (63.6, 74.7) | 9.9 (3.1 to 16.7) | 9.7 (2.6 to 16.8) |
| Non-trial participant | 346 | 584 | 59.3 (55.4, 63.4) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 19 | 40 | 47.5 (32.0, 63.0) | 24.2 (7.7 to 40.6) | 21.5 (4.9 to 38.1) |
| Non-trial participant | 52 | 223 | 23.3 (18.4, 29.6) | 1 | 1 |
| 2015: restricted cohort† | |||||
| All ages | |||||
| Trial participant (control) | 653 | 803 | 81.3 (78.6, 84.0) | 6.9 (3.5 to 10.4) | 4.5 (1.3 to 7.6) |
| Non-trial participant | 1231 | 1655 | 74.4 (72.3, 76.5) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 448 | 503 | 89.1 (86.3, 91.8) | 4.2 (0.7 to 7.8) | 2.5 (−1.2 to 6.2) |
| Non-trial participant | 833 | 982 | 84.8 (82.6, 87.1) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 186 | 264 | 70.5 (65.0, 76.0) | 5.3 (−1.5 to 12.1) | 5.2 (−2.0 to 12.3) |
| Non-trial participant | 346 | 531 | 65.2 (61.2, 69.3) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 19 | 36 | 52.8 (36.5, 69.1) | 16.2 (−2.0 to 34.3) | 13.8 (−5.7 to 33.4) |
| Non-trial participant | 52 | 142 | 36.6 (29.5, 45.5) | 1 | 1 |
School enrolment outcome was analysed in 2011 and 2015 and the analysis was stratified by age, in the full cohort and the cohort restricted to those enrolled in school in 2011.
*Adjusted for socioeconomic status (coded dichotomously at median household asset index score), country of origin (South African vs Mozambican), educational attainment of household head (coded dichotomously at grade 12 attainment), gender of household head (male vs female), household size (coded linearly) and pre-2011 childbearing (yes vs no). Models that are not age-stratified are also adjusted for age coded in 2-year categories.
↵†Restricted to all young women who were enrolled in school in 2011.
aRD, adjusted risk difference; HPTN, HIV Prevention Trial Network; RD, risk difference.